GLP-1 and GIP are incretins: gut hormones that amplify the insulin response to food. Glucagon comes mainly from the pancreas and supports glucose release from the liver. It is not an incretin. These hormones are discussed together because their receptors are targets for mono-, dual and triple agonists [1][3][6]. This overview compares the physiological signals with the molecules that act on their receptors.

Three axes, three molecules

GLP-1 mono

GLP-1R is a class B GPCR. Receptor activation amplifies glucose-dependent insulin secretion; GLP-1 also contributes to glucagon regulation, gastric emptying and food intake [6]. The incretin effect is the larger insulin response to oral glucose than to intravenous glucose reproducing the same blood glucose profile, rather than the same administered quantity [6].

Semaglutide and liraglutide are GLP-1R agonists modified to sustain exposure beyond that of the natural hormone [6]. In STEP 1, semaglutide was given once weekly for 68 weeks and reduced body weight versus placebo in adults with overweight or obesity without diabetes [5]. This is an outcome for a specific medicine and protocol, not a property of every sample sharing its molecule name.

See also: Ozempic ↔ semaglutide.

GLP-1 + GIP (dual)

The GIP receptor was a contested target for years: some preclinical data pointed toward GIP antagonism as the more promising route in obesity, while tirzepatide was designed as a genuine agonist at both receptors in one molecule. A preclinical series on LY3298176 characterized a dual GLP-1/GIP activity profile [1], and the SURMOUNT (obesity) and SURPASS (type 2 diabetes) clinical programs studied the INN tirzepatide in protocol-defined populations; SURMOUNT-1 studied obesity [2].

The unimolecular design means one peptide sequence activates both receptors at once, unlike a hypothetical co-administration of two separate agonists. Tirzepatide's half-life of roughly 5 days supported the once-weekly dosing schedule those programs studied [2]. Exactly how much the GIP component contributes to the weight outcomes, separate from the GLP-1-driven effect, remains an active research question. The laboratory-use vial in our catalog carries the tirzepatide molecule, not the Mounjaro/Zepbound trade name.

Triple agonist (+ glucagon)

Retatrutide (LY3437943) adds glucagon receptor activity on top of GLP-1 and GIP [3][4]. The glucagon receptor is physiologically tied mainly to the liver (glycogenolysis, gluconeogenesis) and to increased energy expenditure, a different mechanism from the largely insulinotropic and satiety-driven effects of GLP-1 and GIP. The rationale for a triple unimolecular agonist is to add an energy-expenditure component on top of the existing appetite and insulin-secretion axes in a single peptide.

Retatrutide has a half-life of approximately 6 days [3][4]. This cannot be inferred from molar mass or the number of receptor targets: molecular structure and pharmacokinetics matter. In a phase 2 trial, retatrutide reduced body weight in adults with obesity [4].

As of 26 October 2026, the programme includes phase 3 trials and reported results. The developer’s September 2026 update states that retatrutide remains investigational and has no regulatory approval. The earlier papers listed below explain the mechanism and phase 2; they are not a complete review of subsequent clinical results.

How the natural hormones differ

HormoneMain sourceReceptorContributes to regulation of
GLP-1Intestinal L cells; a separate brain systemGLP-1RInsulin responses, food intake and gastric emptying
GIPIntestinal K cellsGIPRInsulin responses and nutrient metabolism
GlucagonPancreatic α cellsGCGRHepatic glucose release and amino-acid metabolism

This is a simplified map of physiological roles [6][7]. The receptor activity of a modified co-agonist is not equivalent to administering the natural hormones together.

Why three targets do not mean “better”

The target count describes a mechanism, not a clinical outcome. The strength and duration of activation at each receptor, study population and tolerability matter. Weight-loss percentages from different trials do not form a valid ranking: baseline weight, diabetes status, follow-up duration and methods for accounting for treatment discontinuation may differ [2][4][5].

A direct superiority conclusion requires a head-to-head trial. Even that describes specific doses and conditions, not every product sharing an INN. “GLP-3” is not the name of a separate hormone; retatrutide is more accurately described as a triple GLP-1, GIP and glucagon receptor agonist.

Laboratory use and COA

Every axis in the research catalog ships as a laboratory-use sample: INN on the label, a COA (certificate of analysis) tied to the LOT with purity data. A batch can be checked independently of an order at verify.longeva.bio using the LOT number.

The clinical trial results this primer cites describe study medicines in specific study populations under a defined protocol, which is not the same thing as an arbitrary research batch that happens to share a molecule name. A research-use sample is not a medical product and carries no human dosing regimen.

The catalogue contains research samples of these molecules; their status and intended use must be distinguished from medicines in clinical programmes.